CLINICAL TRIAL OF NY-198 IN PATIENTS WITH RESPIRATORY TRACT INFECTION
スポンサーリンク
概要
- 論文の詳細を見る
We administered NY-198, a newly synthesized pyridonecarboxylic acid antibacterial agent, to patients with respiratory tract infection in order to evaluate its clinical usefulness. Bacterial infections occurring in eight patients included: acute bronchitis (2), chronic bronchitis (4), bronchiectasis (1) and bronchial asthma (1). Investigation of the relevant pathogens by quantitative sputum culture revealed 4 strains of <I>H. influenzae</I>, 2 of <I>P. aeruginosa</I> and 1 each of <I>B. catarrhalis</I> and <I>S. aureus</I>. The patients were treated orally at a daily dose of 300 mg three times a day for 14-16 days. Further bacteriological examination demonstrated that pathogenic bacteria disappeared in 5 of 8 cases, decreased in 1, remained unchanged in 1, and was substituted by <I>S. pneumoniae</I> in 1 case.<BR>Overall clinical efficacy based on improvement in subjective symptoms and disappearance of inflammatory reactions was excellent or good in five cases (62.5%). No side-effect was noted, except for slight impairment of liver function in one case, whose abnormal data did not seem serious because values normalized immediately after discontinuation of the drug.
- 公益社団法人 日本化学療法学会の論文
公益社団法人 日本化学療法学会 | 論文
- DISPOSITION OF 7432-8 IN RATS (I)
- CLINICAL STUDIES ON T-1220 IN SURGICAL CASES
- CLINICAL STUDIES OF PIVALOYLOXYMETHYL D-α-AMINOBENZYL-PENICILLINATE HYDROCHLORIDE IN SURGICAL INFECTIONS
- STUDIES ON AC-1370
- Primary treatment with a combination of cyclophosphamide, vincristine, and dacarbazine for recurrent malignant pheochromocytoma: A case report.